Where to Buy Tirzepatide Research Compound in 2026 — Verification Guide

Tirzepatide (LY3298176) is a dual GLP-1/GIP receptor agonist developed by Eli Lilly that has become one of the most researched metabolic pathway compounds of the past three years. As one of the most-studied incretin-agonist research molecules, tirzepatide has generated substantial published pharmacological and mechanistic data — making it one of the most referenced compounds in in-vitro receptor pharmacology research today.

For qualified laboratory researchers sourcing tirzepatide as a research compound, the verification landscape varies significantly across vendors. This guide covers what documentation should accompany a tirzepatide research compound, how to evaluate vendor quality claims, current market pricing, and what the verification standard should look like for a compound of this research complexity.

For in-vitro and preclinical laboratory research use only. Not for human consumption.

Molecular Profile

• Compound name: Tirzepatide
• Developmental code: LY3298176
• CAS number: 2023788-19-2
• Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular weight: 4813.4 g/mol
• Structure: Synthetic peptide with C18 fatty diacid modification enabling extended half-life
• Receptor targets: GLP-1R and GIPR (dual co-agonist)

The fatty diacid modification is structurally significant — it enables albumin binding that extends the compound’s pharmacokinetic half-life, a property that has informed both clinical dosing research and in-vitro binding studies examining the relationship between structural modification and receptor engagement duration.

Why Tirzepatide Verification Is Particularly Important

Tirzepatide’s structural complexity as a 51-amino acid fatty acid-conjugated peptide makes synthesis quality highly variable across suppliers. The compound’s dual receptor activity means both the peptide sequence integrity and the fatty acid conjugation must be confirmed independently — a more demanding analytical challenge than simpler single-receptor peptides.

Independent testing across multiple research compound vendors has revealed significant purity variation for tirzepatide specifically. Results ranging from 78% to 99.4% across different vendor batches have been documented by community testing platforms, with the lowest results showing structural issues indicating incomplete synthesis or degradation.

For researchers whose experimental designs depend on reproducible receptor binding characteristics, sourcing tirzepatide from a vendor with full analytical documentation — particularly identity confirmation by mass spectrometry — is not optional. HPLC purity alone is insufficient for a structurally complex conjugated peptide.

The Core Testing Requirements for Tirzepatide

HPLC Purity
Chromatographic purity by HPLC should be 98%+ for research-grade tirzepatide. Results below 95% indicate synthesis quality issues that will affect receptor binding reproducibility. The HPLC chromatogram should show a clean primary peak with minimal secondary peaks.

LC-MS Identity Confirmation
For tirzepatide specifically, LC-MS identity confirmation is essential not optional. The compound’s molecular weight of 4813.4 g/mol and its fatty acid conjugation make it susceptible to sequence errors and conjugation failures that HPLC cannot detect but mass spectrometry can. An LC-MS result confirming the correct molecular mass within tolerance is the minimum identity verification standard.

Endotoxin Testing
For cell biology research applications, endotoxin contamination from bacterial sources in the synthesis process is a meaningful experimental confound. Endotoxin results expressed in EU/mg by the LAL method should be included in complete tirzepatide documentation.

Heavy Metals by ICP-MS
Synthesis reagents and equipment can introduce trace metal contamination. For sensitive cell biology systems, ICP-MS heavy metal screening provides confidence that the compound’s receptor binding activity in experimental systems is not confounded by metal-mediated effects.

Current Market Pricing for Tirzepatide Research Compound

The tirzepatide vendor landscape has consolidated significantly following the March 2026 enforcement actions that removed several major suppliers from the market. Current pricing across active vendors:

Market range (10mg lot):

• Low end: $55.99 – $64.99
• Mid range: $74.99 – $89.99
• High end: $109.99 – $149.99

Higher pricing does not correlate reliably with verification quality. Several vendors at the high end of this range provide less comprehensive documentation than vendors at the mid-range. The key variable is verification methodology and laboratory accreditation — not price point.

PYXAX tirzepatide pricing:

• 5mg: $55.99
• 10mg: $64.99
• 20mg: $59.99
• 30mg: $84.99

All lots independently verified by accredited independent laboratories (ISO 17025) before listing.

How to Evaluate a Tirzepatide Vendor

Step 1 — Confirm the testing laboratory is named:
Every vendor claims testing. The question is which laboratory conducted the analysis. For tirzepatide specifically — given its synthesis complexity — the laboratory should be ISO 17025 accredited or hold equivalent recognized accreditation. Unnamed “third-party laboratories” provide no basis for independent verification.

Step 2 — Confirm identity testing method:
Ask specifically whether the COA includes LC-MS identity confirmation, not just HPLC purity. For a 4813 g/mol fatty acid conjugated peptide, HPLC purity without mass spectrometry identity confirmation is insufficient. A vendor that tests only purity is not testing what matters most for tirzepatide.

Step 3 — Verify lot specificity:
The COA batch number should match the vial label. A COA dated before the lot production date, or with a batch number that cannot be traced to your specific order, is not lot-specific documentation.

Step 4 — Check independent verification capability:
Can you verify the result without contacting the vendor? ILS Laboratories COAs include QR codes linking to their verification portal at ils-lab.com. Janoshik Analytical results are searchable at janoshik.com. If the only way to confirm a COA is to contact the vendor — the verification is vendor-controlled, not independent.

Step 5 — Look for endotoxin data:
Given tirzepatide’s frequent use in cell biology research systems, endotoxin data per lot is a meaningful differentiator. Vendors testing only purity and identity are providing incomplete documentation for in-vitro applications.

Red Flags Specific to Tirzepatide Sourcing

Purity below 95%:
Results below 95% HPLC purity for tirzepatide indicate synthesis quality issues. Some vendors present 90-94% purity results without flagging this as below standard. For receptor pharmacology research, purity below 95% will produce inconsistent binding data.

No mass spectrometry identity confirmation:
HPLC can confirm that a peak appears at the expected retention time. It cannot confirm the molecular mass of what is eluting. For tirzepatide’s complex structure, LC-MS confirmation is essential. A COA showing only HPLC purity with no identity confirmation is incomplete.

Test dates preceding vendor launch:
If a vendor launched in 2026 but their tirzepatide COA is dated 2024 — the documentation does not correspond to the compound they are currently shipping. Lot-specific COAs should be dated close to the production date of the specific lot being sold.

All products tested same day:
When every compound in a vendor’s catalog shares the same COA test date, this indicates a single launch testing event rather than ongoing lot-specific quality control. Consistent lot-specific testing produces varied test dates across the catalog.

PYXAX Tirzepatide Verification Standard

PYXAX supplies tirzepatide as a lyophilized research compound with independent third-party verification before listing.

Testing protocol — accredited independent laboratories (ISO 17025):

• Chromatographic purity by HPLC-UV/MS
• Molecular identity by LC-MS
• Endotoxin (USP 85-style LAL method)
• Heavy metals by ICP-MS
• QR-verified, batch-specific COA published for every lot

Lot-specific documentation:
Every production lot receives its own batch number. The batch number appearing on the vial matches the batch number on the COA in the PYXAX COA Library. Researchers can confirm this independently before ordering.

Community verification:
Select lots are submitted to Janoshik Analytical for community verification. Results are publicly searchable at janoshik.com by batch number — no vendor contact required.

Founding batch transparency:
Initial founding batches were verified by Krause Analytical (accredited US laboratory). Ongoing production lots are tested across a network of accredited independent laboratories — including ILS Labs, Krause Analytical, and Janoshik — with a batch-specific COA published for every lot.

Pricing:

• Tirzepatide 5mg: $55.99
• Tirzepatide 10mg: $64.99
• Tirzepatide 20mg: $59.99
• Tirzepatide 30mg: $84.99

View PYXAX Tirzepatide →
View COA Library →
Read The PYXAX Standard →

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.